MRC LONGWY

a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be presenting early results of a new, novel use of the ReShape Lifesciences™ neuro-blocking technology in combination with separate-site vagus nerve stimulation for the treatment of type 2 diabetes. Results of a recent study, which examines this first-ever application for the treatment of type 2 diabetes, will be discussed in a poster presentation during the Minnesota Neuromodulation Symposium taking place at the Graduate Minneapolis Hotel from April 12-13, 2018.
The poster will discuss the use of the ReShape Lifesciences neuro-blocking technology in combination with pacing stimulation of the pancreas as a method to lower plasma glucose in a rat model of type 2 diabetes.
In the study, a proprietary bio-electronic device and algorithm developed by ReShape Lifesciences was used to study for the first time ever the effect of multi-site electrical neuromodulation via the vagus nerve. The study involved the simultaneous nerve pacing and neuro-blocking of two branches of the vagus nerve, innervating the pancreas and the liver, respectively, followed by continuous measurement of plasma glucose. Results showed that glycemic control was significantly increased following an elevated glucose challenge in the ReShape Lifesciences neuromodulation rats compared to those in the control.

For More You Can Check:
3d Animated Explainer